212 related articles for article (PubMed ID: 32762616)
1. LC3B upregulation by NANOG promotes immune resistance and stem-like property through hyperactivation of EGFR signaling in immune-refractory tumor cells.
Kim S; Cho H; Hong SO; Oh SJ; Lee HJ; Cho E; Woo SR; Song JS; Chung JY; Son SW; Yoon SM; Jeon YM; Jeon S; Yee C; Lee KM; Hewitt SM; Kim JH; Song KH; Kim TW
Autophagy; 2021 Aug; 17(8):1978-1997. PubMed ID: 32762616
[TBL] [Abstract][Full Text] [Related]
2. Nanog signaling in cancer promotes stem-like phenotype and immune evasion.
Noh KH; Kim BW; Song KH; Cho H; Lee YH; Kim JH; Chung JY; Kim JH; Hewitt SM; Seong SY; Mao CP; Wu TC; Kim TW
J Clin Invest; 2012 Nov; 122(11):4077-93. PubMed ID: 23093782
[TBL] [Abstract][Full Text] [Related]
3. HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors.
Song KH; Oh SJ; Kim S; Cho H; Lee HJ; Song JS; Chung JY; Cho E; Lee J; Jeon S; Yee C; Lee KM; Hewitt SM; Kim JH; Woo SR; Kim TW
Nat Commun; 2020 Jan; 11(1):562. PubMed ID: 31992715
[TBL] [Abstract][Full Text] [Related]
4. TRAF6 inhibits colorectal cancer metastasis through regulating selective autophagic CTNNB1/β-catenin degradation and is targeted for GSK3B/GSK3β-mediated phosphorylation and degradation.
Wu H; Lu XX; Wang JR; Yang TY; Li XM; He XS; Li Y; Ye WL; Wu Y; Gan WJ; Guo PD; Li JM
Autophagy; 2019 Sep; 15(9):1506-1522. PubMed ID: 30806153
[TBL] [Abstract][Full Text] [Related]
5. HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells.
Song KH; Choi CH; Lee HJ; Oh SJ; Woo SR; Hong SO; Noh KH; Cho H; Chung EJ; Kim JH; Chung JY; Hewitt SM; Baek S; Lee KM; Yee C; Son M; Mao CP; Wu TC; Kim TW
Cancer Res; 2017 Sep; 77(18):5039-5053. PubMed ID: 28716899
[TBL] [Abstract][Full Text] [Related]
6. Stabilization of HDAC1 via TCL1-pAKT-CHFR axis is a key element for NANOG-mediated multi-resistance and stem-like phenotype in immune-edited tumor cells.
Woo SR; Lee HJ; Oh SJ; Kim S; Park SH; Lee J; Song KH; Kim TW
Biochem Biophys Res Commun; 2018 Sep; 503(3):1812-1818. PubMed ID: 30060952
[TBL] [Abstract][Full Text] [Related]
7. 1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells.
Jia Z; Zhang Y; Yan A; Wang M; Han Q; Wang K; Wang J; Qiao C; Pan Z; Chen C; Hu D; Ding X
Cell Death Dis; 2020 Aug; 11(8):670. PubMed ID: 32820157
[TBL] [Abstract][Full Text] [Related]
8. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
9. Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3-NANOG Axis.
Oh SJ; Cho H; Kim S; Noh KH; Song KH; Lee HJ; Woo SR; Kim S; Choi CH; Chung JY; Hewitt SM; Kim JH; Baek S; Lee KM; Yee C; Park HC; Kim TW
Cancer Res; 2018 May; 78(10):2638-2653. PubMed ID: 29437706
[TBL] [Abstract][Full Text] [Related]
10. TP53INP2 contributes to autophagosome formation by promoting LC3-ATG7 interaction.
You Z; Xu Y; Wan W; Zhou L; Li J; Zhou T; Shi Y; Liu W
Autophagy; 2019 Aug; 15(8):1309-1321. PubMed ID: 30767704
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers.
Lefort S; Joffre C; Kieffer Y; Givel AM; Bourachot B; Zago G; Bieche I; Dubois T; Meseure D; Vincent-Salomon A; Camonis J; Mechta-Grigoriou F
Autophagy; 2014; 10(12):2122-42. PubMed ID: 25427136
[TBL] [Abstract][Full Text] [Related]
12. Targeting the NANOG/HDAC1 axis reverses resistance to PD-1 blockade by reinvigorating the antitumor immunity cycle.
Oh SJ; Lee HJ; Song KH; Kim S; Cho E; Lee J; Bosenberg MW; Kim TW
J Clin Invest; 2022 Mar; 132(6):. PubMed ID: 35104240
[TBL] [Abstract][Full Text] [Related]
13. Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease.
Han X; Sun S; Sun Y; Song Q; Zhu J; Song N; Chen M; Sun T; Xia M; Ding J; Lu M; Yao H; Hu G
Autophagy; 2019 Nov; 15(11):1860-1881. PubMed ID: 30966861
[TBL] [Abstract][Full Text] [Related]
14. Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype.
Noh KH; Lee YH; Jeon JH; Kang TH; Mao CP; Wu TC; Kim TW
Cancer Res; 2012 Apr; 72(7):1717-27. PubMed ID: 22337995
[TBL] [Abstract][Full Text] [Related]
15. Metformin alleviates hyperglycemia-induced endothelial impairment by downregulating autophagy via the Hedgehog pathway.
Niu C; Chen Z; Kim KT; Sun J; Xue M; Chen G; Li S; Shen Y; Zhu Z; Wang X; Liang J; Jiang C; Cong W; Jin L; Li X
Autophagy; 2019 May; 15(5):843-870. PubMed ID: 30653446
[TBL] [Abstract][Full Text] [Related]
16. Interaction between SCP3 and JAB1 Confers Cancer Therapeutic Resistance and Stem-like Properties through EGF Expression.
Oh SJ; Noh KH; Song KH; Kim TW
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445562
[TBL] [Abstract][Full Text] [Related]
17. TRPV1 inhibition overcomes cisplatin resistance by blocking autophagy-mediated hyperactivation of EGFR signaling pathway.
Oh SJ; Lim JY; Son MK; Ahn JH; Song KH; Lee HJ; Kim S; Cho EH; Chung JY; Cho H; Kim H; Kim JH; Park J; Choi J; Hwang SW; Kim TW
Nat Commun; 2023 May; 14(1):2691. PubMed ID: 37165076
[TBL] [Abstract][Full Text] [Related]
18. NANOG confers resistance to complement-dependent cytotoxicity in immune-edited tumor cells through up-regulating CD59.
Son SW; Cho E; Cho H; Woo SR; Lee HJ; Oh SJ; Kim S; Kim JH; Chung EJ; Chung JY; Kim MG; Song KH; Kim TW
Sci Rep; 2022 May; 12(1):8652. PubMed ID: 35606403
[TBL] [Abstract][Full Text] [Related]
19. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
[TBL] [Abstract][Full Text] [Related]
20. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N
Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
